← All Companies
Roivant Sciences Ltd.
ROIV · Nasdaq · SIC 2834: Pharmaceutical Preparations
Business Summary PART I References to Roivant, the Company, we, us or our in the following section refer to Roivant Sciences Ltd. and its consolidated subsidiaries, unless the context otherwise requires. Overview Roivant is a biopharmaceutical company that aims to improve the lives of patients by accelerating the development and commercialization of medicines that matter. Roivants pipeline includes brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositi...
Next Earnings Q2 FY2026 — expected 2026-09-10
Key Facts from Earnings Calls Type Subject Detail Quarter topic_mention ROIV discussed_in_filing Artificial Intelligence topic_mention ROIV discussed_in_filing Cybersecurity topic_mention ROIV discussed_in_filing Trusted Computing topic_mention ROIV discussed_in_filing Blockchain & Crypto topic_mention ROIV discussed_in_filing Regulation topic_mention ROIV discussed_in_filing Healthcare & Bio topic_mention ROIV discussed_in_filing Sovereign & Government topic_mention ROIV discussed_in_filing Artificial Intelligence topic_mention ROIV discussed_in_filing Cybersecurity topic_mention ROIV discussed_in_filing Trusted Computing topic_mention ROIV discussed_in_filing Blockchain & Crypto topic_mention ROIV discussed_in_filing Regulation topic_mention ROIV discussed_in_filing Healthcare & Bio topic_mention ROIV discussed_in_filing Sovereign & Government topic_mention ROIV discussed_in_filing Artificial Intelligence topic_mention ROIV discussed_in_filing Cybersecurity topic_mention ROIV discussed_in_filing Trusted Computing topic_mention ROIV discussed_in_filing Blockchain & Crypto topic_mention ROIV discussed_in_filing Regulation topic_mention ROIV discussed_in_filing Healthcare & Bio
Annual Reports (10-K) Filed Period Accession Source Full Text 2025-05-29 2025-03-31 0001140361-25-020715 EDGAR 145K words 2024-05-30 2024-03-31 0001140361-24-028145 EDGAR — 2023-06-28 2023-03-31 0001140361-23-031798 EDGAR — 2022-06-28 2022-03-31 0001193125-22-183362 EDGAR —
Quarterly Reports (10-Q) Filed Period Accession Source Full Text 2026-02-06 2025-12-31 0001635088-26-000011 EDGAR 86K words 2025-11-10 2025-09-30 0001635088-25-000016 EDGAR — 2025-08-11 2025-06-30 0001140361-25-030001 EDGAR — 2025-02-10 2024-12-31 0001140361-25-003661 EDGAR — 2024-11-12 2024-09-30 0001140361-24-046019 EDGAR — 2024-08-09 2024-06-30 0001140361-24-036642 EDGAR — 2024-02-13 2023-12-31 0001140361-24-007260 EDGAR — 2023-11-13 2023-09-30 0001140361-23-052721 EDGAR — 2023-08-14 2023-06-30 0001140361-23-039406 EDGAR — 2023-02-13 2022-12-31 0001140361-23-006180 EDGAR — 2022-11-14 2022-09-30 0001140361-22-041175 EDGAR — 2022-08-15 2022-06-30 0001193125-22-220561 EDGAR —
Recent Current Reports (8-K) Filed Accession Source Full Text 2026-04-02 0001140361-26-012885 EDGAR 1K words 2026-03-03 0001140361-26-007548 EDGAR — 2026-03-03 0001140361-26-007447 EDGAR — 2026-02-06 0001635088-26-000009 EDGAR — 2025-12-11 0001140361-25-045204 EDGAR — 2025-11-10 0001140361-25-041269 EDGAR — 2025-09-17 0001140361-25-035190 EDGAR — 2025-09-11 0001140361-25-034711 EDGAR — 2025-09-03 0001140361-25-033767 EDGAR — 2025-08-11 0001140361-25-029998 EDGAR —
112 total filings indexed. 86 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
Sector Peers Company Identity
CIK 0001635088
Ticker ROIV
Exchange Nasdaq
SIC 2834: Pharmaceutical Preparations
Incorporated D0
Get More Data
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile
Stock Quote
AI Readiness Report
Origin Provenance
page leaf: 651adf2b97547eb8aa5a5e6520a663e1382a85a9f8402069d541562187764f23
parent: 300c9b13a34b66c10568f1aacf789428ca0e7a9c56d1f4632aa689abd451c183
content hash: ac6b05c58a3756f30af951840039b45d4a69b2fd61495dc13e7b914589912c9f
signed: 2026-04-13T04:47:14.601Z
sources: 16 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf